Navigation Links
Chimerix's Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
Date:12/13/2010

DURHAM, N.C., Dec. 13, 2010 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced first-in-human Phase 1 clinical trial results for CMX157 demonstrating a favorable safety, tolerability and drug distribution profile. In addition, results from a series of preclinical studies showed that CMX157 exhibited highly potent in vitro activity against human immunodeficiency virus (HIV), including HIV strains resistant to current therapies, and potent in vitro activity against xenotropic murine leukemia virus-related virus (XMRV), a blood-borne retrovirus recently associated with chronic fatigue syndrome (CFS).CMX157 clinical and preclinical findings were presented in an oral abstract, titled "CMX157 (HexadecyloxypropylTenofovir), a Clinical Stage Antiretroviral with In Vitro Activity against HIV and XMRV" at the HIV DART™ 2010 Frontiers in Drug Development for Antiretroviral Therapies conference.  

"CMX157's promising safety profile and efficient conversion to the active drug in peripheral blood mononuclear cells, coupled with the potent in vitro antiviral activity across diverse drug-resistant strains of HIV, indicate that this compound may directly address the limitations of current HIV therapies," said Randall Lanier, Ph.D., Senior Director of Virology of Chimerix.  "We are also excited about CMX157's in vitro antiviral activity against XMRV, a retrovirus recently associated with chronic fatigue syndrome."

"Our CMX001 and CMX157 programs are producing compelling clinical and preclinical evidence of how Chimerix's PIM Conjugate Technology transforms the way compounds are absorbed, distributed, metabolized and excreted, creating new agents with improved antiviral action and reduced toxicities.  The promising clinical and preclinical data being reported for CMX157 strengthen our commitment to advancing this novel antiviral for
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
2. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
3. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
4. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
5. BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
6. ViroDefense Inc Announces Selection of Poliovirus Antiviral Preclinical Candidate
7. Positive Phase I/II Data of IDX899 Confirm Potent Antiviral Activity and Favorable Safety Profile in Treatment-Naive HIV-Infected Patients
8. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
9. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
10. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
11. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... , July 14, 2014  GenSpera, Inc. (OTCQB: ... the treatment of cancer, announces that Kareg Corporation,s ... has issued the following research report on  the ... , Director of Research, Kareg Corporation, Initiating Coverage ... Read the full report: http://www.genspera.com/press/140711_Genspera_research_report_July2014.pdf ...
(Date:7/14/2014)... -- Medac Pharma, Inc., a privately held pharmaceutical company ... improving the effectiveness of existing medicines, announced that ... approved Rasuvo™, a subcutaneous injectable methotrexate (MTX) therapy ... polyarticular-course juvenile idiopathic arthritis (pJIA) and psoriasis. Rasuvo ... from 7.5 mg to 30 mg in 2.5 ...
(Date:7/14/2014)... Ill., July 14, 2014  Abbott (NYSE: ABT) announced today ... pharmaceuticals business to Mylan for equity ownership of a ... and Abbott,s developed markets pharmaceuticals ... represents a value of approximately $5.3 billion based on ... portion of this business generated approximately $2 billion in ...
Breaking Medicine Technology:Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 2Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 3Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 4Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 5Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 6Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 2Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 3Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 4Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 5Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 6Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 7Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 8Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 2Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 3Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 4Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 5Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 6Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 7
... Va., Aug. 26 Radiation in any form brings risk. ... designed with safeguards in mind to minimize the risk and ... if a patient presents with a breast lump that can ... professionals must employ the most appropriate diagnostic tools that identify ...
... Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company -- JERUSALEM, August 26, 2010 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, ...
Cached Medicine Technology:Media Statement: Robert Moussa, President and CEO, Dilon Diagnostics 2Media Statement: Robert Moussa, President and CEO, Dilon Diagnostics 3Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company 2Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company 3Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company 4Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company 5Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company 6
(Date:7/14/2014)... The report “Biofertilizers Market ... Type (Cereals & Grains, Pulses & Oilseeds, ... Azospirillium, Cyanobacteria, Phosphate solubilizing bacteria), & by ... 2019” defines and segments the biofertilizers market ... values for the market. It also identifies ...
(Date:7/14/2014)... E.J. Mundell ... News) -- When an 11-year-old boy in San Diego ... the nickel in his family,s iPad. They also ... iPad,s metal surfaces with a form-fitting case. The ... personal effects as potential sources of nickel exposure" and ...
(Date:7/14/2014)... specialists look back on 40 years of the Glasgow Coma ... research and clinical practice, in a new Personal View published ... The Personal View is published on the 40th anniversary of ... Since this seminal publication, the Glasgow Coma Scale has ... conscious level, the clinical hallmark of acute brain injury. The ...
(Date:7/14/2014)... to ignore irrelevant stimuli underlies the impaired working memory ... reports a new study in the current issue of ... good at focusing on the information that we are ... thoughts that aren,t relevant. However, memory impairment in schizophrenia ... this filtering process, which Dr. Teal Eich at Columbia ...
(Date:7/14/2014)... N.J. (PRWEB) July 14, 2014 Documented ... Laurel, has announced the publication of its first military memoir ... crash on Black Thursday in October 1943 and 19 months ... to return home and build the American dream. , ... and the American dream (Amazon) is a true ...
Breaking Medicine News(10 mins):Health News:Biofertilizers Market worth $1,649.7 Million by 2019 - A Report by MarketsandMarkets 2Health News:Biofertilizers Market worth $1,649.7 Million by 2019 - A Report by MarketsandMarkets 3Health News:Biofertilizers Market worth $1,649.7 Million by 2019 - A Report by MarketsandMarkets 4Health News:iPads Can Trigger Nickel Allergies in Kids 2Health News:'Noisy' memory in schizophrenia 2Health News:Mount Laurel-based Documented Legacy to Release Military Memoir of World War II Air Force Vet Who Survived Black Thursday Crash 2
... HealthDay Reporter , FRIDAY, March 16 (HealthDay ... for kids who have a genetic predisposition to aggressive ... new research suggests. "There,s an intricate interplay between ... assistant professor of criminology at the University of Texas ...
... Musicians and their instruments often make beautiful music together, but ... of musical instruments may put their owners at risk for ... Contact dermatitis is a rash caused by an irritant or ... components of musical instruments -- such as metals, exotic woods ...
... Obesity appears to significantly increase the risk of death ... mortality even among those prescribed 18 or fewer pills ... as a marker of increased vulnerability," said Robert Langer, ... and Prevention | Nutrition, Physical Activity and Metabolism 2012 ...
... companies in overcoming common issues associated with crystal formation ... The software, which has been developed at the University ... Centre (CCDC) is called Visual HABIT. It offers a ... companies to adopt a more ,bottom up, approach to ...
... , FRIDAY, March 16 (HealthDay News) -- People with ... risk for health problems that affect the heart, an ... of psoriasis. Chronic inflammation is also a characteristic of ... said Dr. Joel Gelfand, an assistant professor of dermatology ...
... facilitate efficient production of chemicals, materials and fuels from ... Excellence (CoE) in White Biotechnology Green Chemistry Research ... or cell factories, for producing new useful compounds from ... for example, for manufacturing bioplastics or in medical applications. ...
Cached Medicine News:Health News:With Spanking, Nature and Nurture Create More Aggression, Study Suggests 2Health News:With Spanking, Nature and Nurture Create More Aggression, Study Suggests 3Health News:Tooting Your Horn Can Raise Risk for Skin Condition 2Health News:Obesity raises death risk tied to sleeping pills 2Health News:Obesity raises death risk tied to sleeping pills 3Health News:New technology to aid crystallization prediction 2Health News:Psoriasis Patients May Face Higher Heart Risk 2Health News:Novel plastics and textiles from waste with the use of microbes 2
This double-up gel dryer system, 100-120 V, includes 2 Model 583 gel dryers, HydroTech™ vacuum pump, and double-up rack....
... GelAir™ drying system utilizes a hot air drying ... dried on a clear cellophane support for easy ... a smooth, flat assembly surface for the drying ... frames at once. This 115 V, 60 Hz ...
... is an electrophoresis gel vacuum dryer that removes ... these gels onto cellophane or filter paper for ... which heat gels from above. The drying surface ... unit includes power cord, porous gel support, transparent ...
... The PRO6000 power supply is ... power supply product offering. It ... and genomic electrophoresis. This product ... proteomic applications such as microAmp ...
Medicine Products: